Uqar spinout Ovensa has obtained $1.38m of additional funding from investors including commercialisation firm Aligo Innovation.
Ovensa, a Canada-based oncology-focused spinout from Université du Québec à Rimouski (Uqar), has achieved a $1.38m close in a funding round that featured commercialisation firm Aligo Innovation.
The round included 22 angel entrepreneurs from Anges Québec and the network’s institutional fund, Anges Québec Capital. Uqar is one of 11 university partners of Aligo.
Ovensa is working on nanotherapeutics that break through biological hurdles such as blood-brain barriers and mucous membranes. The platform, called Triozan, could help fight brain tumours and…
